The Development of Prophylactic EBV VaccinesMan Wang1* and Shuai Jiang2
- *Corresponding Author:
- Man Wang
Institute for Translational Medicine
Medical College of Qingdao University
Qingdao, 266021, China
E-mail: [email protected]
Received date:October 26, 2015; Accepted date:October 29, 2015; Published date: November 02, 2015
Citation: Wang M, Jiang S (2015) The Development of Prophylactic EBV Vaccines. Immunol Disord Immunother 1:e101. doi:10.4172/IDIT.1000e101
Copyright: © 2015 Wang M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Epstein-Barr virus (EBV) is an important global human pathogen found in over 90% of the world’s population. EBV infection usually occurs in young children and causes no or only nonspecific symptoms. However, EBV is the major cause of infectious mononucleosis (IM).